These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22228203)

  • 1. A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.
    Aslibekyan S; Kabagambe EK; Irvin MR; Straka RJ; Borecki IB; Tiwari HK; Tsai MY; Hopkins PN; Shen J; Lai CQ; Ordovas JM; Arnett DK
    Pharmacogenet Genomics; 2012 Mar; 22(3):191-7. PubMed ID: 22228203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary evidence of genetic determinants of adiponectin response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.
    Aslibekyan S; An P; Frazier-Wood AC; Kabagambe EK; Irvin MR; Straka RJ; Tiwari HK; Tsai MY; Hopkins PN; Borecki IB; Ordovas JM; Arnett DK
    Nutr Metab Cardiovasc Dis; 2013 Oct; 23(10):987-94. PubMed ID: 23149075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.
    Yusuf N; Hidalgo B; Irvin MR; Sha J; Zhi D; Tiwari HK; Absher D; Arnett DK; Aslibekyan SW
    Pharmacogenomics; 2017 Sep; 18(14):1333-1341. PubMed ID: 28835163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.
    Aslibekyan S; Goodarzi MO; Frazier-Wood AC; Yan X; Irvin MR; Kim E; Tiwari HK; Guo X; Straka RJ; Taylor KD; Tsai MY; Hopkins PN; Korenman SG; Borecki IB; Chen YD; Ordovas JM; Rotter JI; Arnett DK
    PLoS One; 2012; 7(10):e48663. PubMed ID: 23119086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.
    Frazier-Wood AC; Aslibekyan S; Borecki IB; Hopkins PN; Lai CQ; Ordovas JM; Straka RJ; Tiwari HK; Arnett DK
    Pharmacogenet Genomics; 2012 Oct; 22(10):750-7. PubMed ID: 22890011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.
    Irvin MR; Zhang Q; Kabagambe EK; Perry RT; Straka RJ; Tiwari HK; Borecki IB; Shimmin LC; Stuart C; Zhong Y; Hixson JE; Arnett DK
    Pharmacogenet Genomics; 2012 May; 22(5):367-72. PubMed ID: 22336959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Levels of Soluble Interleukin-2 Receptor α: Associations With Clinical Cardiovascular Events and Genome-Wide Association Scan.
    Durda P; Sabourin J; Lange EM; Nalls MA; Mychaleckyj JC; Jenny NS; Li J; Walston J; Harris TB; Psaty BM; Valdar W; Liu Y; Cushman M; Reiner AP; Tracy RP; Lange LA
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2246-53. PubMed ID: 26293465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.
    Irvin MR; Rotroff DM; Aslibekyan S; Zhi D; Hidalgo B; Motsinger-Reif A; Marvel S; Srinivasasainagendra V; Claas SA; Buse JB; Straka RJ; Ordovas JM; Borecki IB; Guo X; Chen IY; Rotter JI; Wagner MJ; Arnett DK
    Pharmacogenet Genomics; 2016 Jul; 26(7):324-33. PubMed ID: 27002377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.
    Smith JA; Arnett DK; Kelly RJ; Ordovas JM; Sun YV; Hopkins PN; Hixson JE; Straka RJ; Peacock JM; Kardia SL
    Eur J Hum Genet; 2008 May; 16(5):603-13. PubMed ID: 18212815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study.
    Frazier-Wood AC; Ordovas JM; Straka RJ; Hixson JE; Borecki IB; Tiwari HK; Arnett DK
    Pharmacogenomics J; 2013 Aug; 13(4):312-7. PubMed ID: 22547144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
    Belfort R; Berria R; Cornell J; Cusi K
    J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
    Okopień B; Krysiak R; Herman ZS
    J Clin Endocrinol Metab; 2006 May; 91(5):1770-8. PubMed ID: 16492702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents.
    Shen J; Ordovas JM
    Clin Chem; 2009 Feb; 55(2):256-64. PubMed ID: 19074515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte suppressing action of fenofibrate.
    Okopień B; Kowalski J; Krysiak R; Łabuzek K; Stachura-Kułach A; Kułach A; Zieliński M; Herman ZS
    Pharmacol Rep; 2005; 57(3):367-72. PubMed ID: 15985720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.
    Liu Y; Ordovas JM; Gao G; Province M; Straka RJ; Tsai MY; Lai CQ; Zhang K; Borecki I; Hixson JE; Allison DB; Arnett DK
    Pharmacogenet Genomics; 2009 Feb; 19(2):161-9. PubMed ID: 19057464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients.
    Rosenson RS
    Obesity (Silver Spring); 2009 Mar; 17(3):504-9. PubMed ID: 19023279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.
    Irvin MR; Kabagambe EK; Tiwari HK; Parnell LD; Straka RJ; Tsai M; Ordovas JM; Arnett DK
    Circ Cardiovasc Genet; 2010 Oct; 3(5):462-7. PubMed ID: 20729559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
    Krysiak R; Gdula-Dymek A; Marek B; Okopień B
    Endokrynol Pol; 2015; 66(3):224-30. PubMed ID: 26136131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.
    Tsai MY; Ordovas JM; Li N; Straka RJ; Hanson NQ; Arends VL; Arnett D
    Mol Genet Metab; 2010 Jun; 100(2):118-22. PubMed ID: 20346718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
    Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.